Form 4: Lifecore Biomedical Director Acquires Significant Restricted Stock Units

Paul Harold Johnson, a Director at Lifecore Biomedical, Inc., acquired 19,506 restricted stock units, increasing his direct beneficial ownership to 44,060 shares.

Summary

• Paul Harold Johnson, a Director of Lifecore Biomedical, Inc. (LFCR), acquired 19,506 restricted stock units (RSUs) on July 15, 2025.
• These restricted stock units convert into common stock on a one-for-one basis.
• The RSUs are scheduled to vest on the earlier of the one-year anniversary of the acquisition date (July 15, 2026) or the date of the company's annual meeting of stockholders in calendar year 2026, provided that date is no less than 50 weeks from the acquisition date.
• Following this transaction, Mr. Johnson directly beneficially owns a total of 44,060 shares of Lifecore Biomedical, Inc. common stock.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director is generally a positive signal, indicating confidence and aligning interests, though it's a routine compensation event rather than a major strategic announcement.

Positives

• A Director, Paul Harold Johnson, acquired 19,506 restricted stock units, indicating continued alignment of management interests with shareholder value.
• The acquisition increases the director's direct beneficial ownership to 44,060 shares, demonstrating confidence in the company's future prospects.

Future Outlook

The vesting schedule for the acquired restricted stock units indicates a future commitment from the director, with vesting expected by the earlier of July 15, 2026, or the 2026 annual meeting, aligning the director's long-term interests with the company's performance.

Industry Context

This transaction is a routine insider filing, common across industries, where directors receive equity compensation to align their interests with long-term company performance and shareholder value. It does not provide specific insights into broader industry trends for the biomedical sector but reflects standard corporate governance practices.

Comparison to Industry Standards

• The acquisition of restricted stock units by a director is a standard practice in corporate compensation across various industries, including the biomedical sector.
• This method aligns executive incentives with long-term shareholder value, similar to practices observed in companies like Medtronic (MDT) or Boston Scientific (BSX), where equity awards are a significant component of executive compensation.
• The vesting schedule, typically over one year or tied to annual meetings, is also a common structure designed to retain talent and encourage sustained performance.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value due to the acquisition of equity.
• Employees: No specific impact on employees is mentioned in this filing.
• Customers: No specific impact on customers is mentioned in this filing.
• Suppliers: No specific impact on suppliers is mentioned in this filing.
• Creditors: No specific impact on creditors is mentioned in this filing.

Next Steps

• Monitoring the vesting of the acquired restricted stock units by July 15, 2026, or the 2026 annual meeting.

Key Dates

Recommendation

Keywords

Lifecore Biomedical, LFCR, SEC Form 4, Insider Transaction, Restricted Stock Units, Director Compensation, Equity Acquisition, Beneficial Ownership